- What the product does (core value proposition in objective terms)
- MetaNovas is an AI and biotechnology company focused on discovering, developing, and commercializing bioactive ingredients, particularly peptides, for beauty/personal care and adjacent consumer health categories. The company also describes an "AI Agent OS" concept intended to coordinate brand strategy, marketing, R&D, content creation, and operations workflows for consumer brands.
- Public materials describe capabilities spanning scientific knowledge extraction, knowledge-graph reasoning, multi-omics analytics, and peptide design that integrates generative AI and simulation. Company materials and press releases identify four technology platforms: MetaNLP, MetaKG, MetaOmics, and MetaPep.
- Target market and market positioning
- Primary buyers appear to include:
- Beauty/personal care and consumer health companies seeking novel active ingredients and accelerated R&D cycles.
- Ingredient distributors and intermediaries seeking differentiated actives for their portfolios.
- Market positioning appears to combine AI-driven discovery workflows with ingredient commercialization; the company operates more like an ingredient innovator than a pure software vendor.
- Company background (founding year, HQ, key leadership)
- Founding year
- Multiple sources indicate 2021.
- Geography / HQ (inconsistent across sources)
- Third-party directories list Shanghai, China as a headquarters location.
- Industry media list a Mountain View, CA address.
- A press release references Foster City, California.
- A Chinese venture/industry database states founding activity in Boston and Shanghai.
- Leadership
- LinkedIn and industry press list Lun Yu as Co-Founder & CTO.
- CB Insights lists Meijie Wang as Co-Founder & CEO.
- Funding and growth: investment rounds, acquisitions, estimated customer count/revenue if public
- Funding
- A Chinese venture/industry database reports an angel round in early 2022, an A round in late 2024 (amount undisclosed), and an A+ round in early 2026 (amount undisclosed; specific investor names are omitted here).
- Public databases show an early-stage funding figure and a Series A - II stage classification; this may not reflect later China-reported rounds.
- Revenue / customer count
- No audited revenue, customer count, or ARR figures were found in accessible primary sources.
- One technology news page claimed MetaNovas reached substantial ARR; methodology and substantiation were not accessible and this should be treated as unverified.
- Acquisitions
- No acquisitions were found in accessible sources.
- Pricing model with specific tiers and costs where available
- Pricing is not publicly posted on the company website in the accessible sources used for this research.
- The company appears to monetize via:
- B2B ingredient partnerships and commercialization agreements.
- Enterprise licensing or service engagements for its "AI Agent OS" workflows.
- Buyer takeaway: expect custom enterprise pricing tied to program scope (ingredient program, exclusivity, geography, volume commitments, validation work, and/or software access).
- Total cost of ownership considerations (implementation, training, hidden costs)
- For ingredient collaborations
- Typical hidden costs likely include:
- Laboratory validation, stability testing, safety dossiers, claim substantiation studies, and regulatory work.
- Scale-up, manufacturing qualification, and quality control/assurance.
- Intellectual property and exclusivity premiums.
- For any workflow or platform software
- Typical TCO risks include:
- Data integration (internal brand assets, formulations, regulatory databases, PLM/ERP).
- Organizational change management across R&D, marketing, and regulatory functions.
- Governance and review processes to prevent non-compliant claims.
- Key competitors in the space (list 4-6 direct alternatives)
- Nuritas (AI peptide discovery for food/health and other applications).
- Pepticom (AI-driven peptide drug discovery; pharma orientation).
- Schrödinger (computational platform for molecular discovery/design; broader drug & materials focus).
- Insilico Medicine (suite for drug discovery; pharma orientation).
- Cradle (protein engineering platform; adjacent for biologics/protein design workflows).